Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) SVP Michael Patrick Miller sold 200 shares of the company’s stock in a transaction on Monday, September 19th. The stock was sold at an average price of $126.17, for a total transaction of $25,234.00. Following the transaction, the senior vice president now owns 17,325 shares of the company’s stock, valued at $2,185,895.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Michael Patrick Miller also recently made the following trade(s):

  • On Monday, August 15th, Michael Patrick Miller sold 100 shares of Jazz Pharmaceuticals PLC stock. The stock was sold at an average price of $136.45, for a total transaction of $13,645.00.
  • On Friday, July 15th, Michael Patrick Miller sold 100 shares of Jazz Pharmaceuticals PLC stock. The stock was sold at an average price of $142.43, for a total transaction of $14,243.00.

Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) opened at 126.31 on Wednesday. Jazz Pharmaceuticals PLC has a one year low of $108.50 and a one year high of $160.00. The company has a 50 day moving average of $132.25 and a 200-day moving average of $139.74. The stock has a market cap of $7.65 billion, a price-to-earnings ratio of 22.21 and a beta of 0.93.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/jazz-pharmaceuticals-plc-jazz-svp-michael-patrick-miller-sells-200-shares.html

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last released its quarterly earnings results on Tuesday, August 9th. The specialty pharmaceutical company reported $2.63 EPS for the quarter, missing the consensus estimate of $2.80 by $0.17. The company had revenue of $381 million for the quarter, compared to analyst estimates of $376.40 million. Jazz Pharmaceuticals PLC had a return on equity of 28.39% and a net margin of 25.46%. The business’s revenue was up 14.2% on a year-over-year basis. During the same period last year, the firm posted $2.41 earnings per share. On average, analysts anticipate that Jazz Pharmaceuticals PLC will post $10.08 earnings per share for the current year.

A number of equities analysts have weighed in on the stock. Mizuho restated a “buy” rating and set a $185.00 price objective on shares of Jazz Pharmaceuticals PLC in a research report on Thursday, September 15th. BMO Capital Markets restated an “outperform” rating and set a $195.00 price objective (up from $193.00) on shares of Jazz Pharmaceuticals PLC in a research report on Thursday, September 8th. Leerink Swann restated an “outperform” rating and set a $202.00 price objective on shares of Jazz Pharmaceuticals PLC in a research report on Wednesday, September 7th. Janney Montgomery Scott assumed coverage on shares of Jazz Pharmaceuticals PLC in a research report on Thursday, August 25th. They set a “neutral” rating for the company. Finally, Deutsche Bank AG restated a “buy” rating and set a $158.00 price objective (up from $155.00) on shares of Jazz Pharmaceuticals PLC in a research report on Thursday, August 11th. One analyst has rated the stock with a sell rating, two have given a hold rating and fourteen have issued a buy rating to the stock. Jazz Pharmaceuticals PLC currently has an average rating of “Buy” and an average target price of $185.67.

Institutional investors have recently added to or reduced their stakes in the company. BlackRock Fund Advisors raised its position in Jazz Pharmaceuticals PLC by 3.2% in the first quarter. BlackRock Fund Advisors now owns 1,527,156 shares of the specialty pharmaceutical company’s stock valued at $199,370,000 after buying an additional 47,265 shares during the period. State Street Corp raised its position in Jazz Pharmaceuticals PLC by 7.7% in the first quarter. State Street Corp now owns 1,333,938 shares of the specialty pharmaceutical company’s stock valued at $174,128,000 after buying an additional 95,849 shares during the period. Bank of New York Mellon Corp raised its position in Jazz Pharmaceuticals PLC by 4.2% in the second quarter. Bank of New York Mellon Corp now owns 1,233,053 shares of the specialty pharmaceutical company’s stock valued at $174,242,000 after buying an additional 49,967 shares during the period. JPMorgan Chase & Co. raised its position in Jazz Pharmaceuticals PLC by 20.0% in the first quarter. JPMorgan Chase & Co. now owns 1,074,731 shares of the specialty pharmaceutical company’s stock valued at $140,307,000 after buying an additional 179,454 shares during the period. Finally, Prudential Financial Inc. raised its position in Jazz Pharmaceuticals PLC by 2.0% in the second quarter. Prudential Financial Inc. now owns 620,397 shares of the specialty pharmaceutical company’s stock valued at $87,668,000 after buying an additional 12,320 shares during the period. 88.25% of the stock is currently owned by hedge funds and other institutional investors.

About Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

5 Day Chart for NASDAQ:JAZZ

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.